For individuals with a GPV in CHEK2 or ATM, we provide best practice guidance which favours providing information regarding prostate cancer risk at a results appointment with patient-initiated follow-up (PIFU) if and when required. This evidence concerns the gene CHEK2 and prostate carcinoma.